FDA Panel Votes 17-6 Obesity Drugmakers Should Study Heart Risks; Watch Orexigen (OREX, VIVUS (VVUS), Arena (ARNA)

March 29, 2012 3:38 PM EDT Send to a Friend
An FDA panel has just voted 17-6 that obesity drugmakers should study heart risks.

Traders should watch Orexigen (Nasdaq: OREX), VIVUS (Nasdaq: VVUS) and Arena (Nasdaq: ARNA).

UPDATE: Orexigen shares closed down 1 percent, VIVUS shares closed up 4 percent, and Arena shares closed up 4 percent.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Corporate News, FDA, Hot FDA News

Add Your Comment